Listen
IASOTOC (gallium (68Ga) edotreotide), diagnostic product for tumour detection
DIAGNOSIS - New medicinal product
Opinions on drugs -
Posted on
Jun 15 2017
Reason for request
Inclusion
No clinical benefit demonstrated in the diagnostic management of neuroendocrine tumours and meningiomas
- IASOTOC has a Marketing Authorisation in the diagnosis of neuroendocrine tumours and meningiomas.
- It is intended for positron emission tomography (PET) and binds specifically to somatostatin receptors.
- Studies have not demonstrated any benefit in relation to its clinically relevant comparators.
- No conclusive results are available on its possible impact on the organisation of the care system in terms of optimising therapeutic management in the treatment of neuroendocrine tumours and meningiomas
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
